Literature DB >> 23578490

Fmr1 deletion enhances and ultimately desensitizes CB(1) signaling in autaptic hippocampal neurons.

Alex Straiker1, Kyung-Tai Min, Ken Mackie.   

Abstract

Fragile X Syndrome (FXS) is a heritable form of mental retardation caused by a non-coding trinucleotide expansion of the FMR1 gene leading to loss of expression of this RNA binding protein. Mutations in this gene are strongly linked to enhanced Group I metabotropic glutamate receptor (mGluR) signaling. A recent report found that mGluR5-dependent endogenous cannabinoid signaling is enhanced in hippocampal slices from fmr1 knockout mice, suggesting a link between FXS and cannabinoid signaling. Alterations in cannabinoid signaling have an impact on learning and memory and may therefore be linked to some aspects of the FXS phenotype. We have used autaptic hippocampal neurons cultured from fmr1 knockout mice to further explore the interaction between endocannabinoid signaling and FMRP. These neurons express several robust forms of retrograde endocannabinoid signaling including depolarization induced suppression of excitation (DSE) and a metabotropic form (MSE) that results from Group I mGluR activation. We now report that young fmr1 neurons exhibit considerably enhanced DSE, likely via increased production of 2-AG, rather than enhanced mGluR-MSE. We find that depolarizations as brief as 50ms, which do not ordinarily produce DSE, routinely inhibited glutamate release. Furthermore, as neuronal cultures mature, CB1-receptor signaling strongly desensitizes. Our results suggest that loss of FMRP broadly affects the endocannabinoid signaling system, possibly through local 2-AG over production. Furthermore, the net effect of the loss of FMRP may actually be diminished cannabinoid signaling due to receptor desensitization as an adaptation to 2-AG overproduction.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23578490      PMCID: PMC3702050          DOI: 10.1016/j.nbd.2013.04.002

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  33 in total

1.  Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells.

Authors:  A C Kreitzer; W G Regehr
Journal:  Neuron       Date:  2001-03       Impact factor: 17.173

2.  Altered synaptic plasticity in a mouse model of fragile X mental retardation.

Authors:  Kimberly M Huber; Sean M Gallagher; Stephen T Warren; Mark F Bear
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

3.  A family with fragile-X syndrome.

Authors:  J Kerbeshian; L Burd; J Martsolf
Journal:  J Nerv Ment Dis       Date:  1984-09       Impact factor: 2.254

4.  Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors.

Authors:  T Maejima; K Hashimoto; T Yoshida; A Aiba; M Kano
Journal:  Neuron       Date:  2001-08-16       Impact factor: 17.173

5.  Calcium dependence of retrograde inhibition by endocannabinoids at synapses onto Purkinje cells.

Authors:  Stephan D Brenowitz; Wade G Regehr
Journal:  J Neurosci       Date:  2003-07-16       Impact factor: 6.167

6.  Brain monoglyceride lipase participating in endocannabinoid inactivation.

Authors:  T P Dinh; D Carpenter; F M Leslie; T F Freund; I Katona; S L Sensi; S Kathuria; D Piomelli
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-22       Impact factor: 11.205

Review 7.  On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures.

Authors:  Beat Lutz
Journal:  Biochem Pharmacol       Date:  2004-11-01       Impact factor: 5.858

8.  Chemical transmission between rat sympathetic neurons and cardiac myocytes developing in microcultures: evidence for cholinergic, adrenergic, and dual-function neurons.

Authors:  E J Furshpan; P R MacLeish; P H O'Lague; D D Potter
Journal:  Proc Natl Acad Sci U S A       Date:  1976-11       Impact factor: 11.205

Review 9.  The mGluR theory of fragile X mental retardation.

Authors:  Mark F Bear; Kimberly M Huber; Stephen T Warren
Journal:  Trends Neurosci       Date:  2004-07       Impact factor: 13.837

10.  Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain.

Authors:  Tiziana Bisogno; Fiona Howell; Gareth Williams; Alberto Minassi; Maria Grazia Cascio; Alessia Ligresti; Isabel Matias; Aniello Schiano-Moriello; Praveen Paul; Emma-Jane Williams; Uma Gangadharan; Carl Hobbs; Vincenzo Di Marzo; Patrick Doherty
Journal:  J Cell Biol       Date:  2003-11-10       Impact factor: 10.539

View more
  12 in total

1.  Endocannabinoid-mediated improvement on a test of aversive memory in a mouse model of fragile X syndrome.

Authors:  Mei Qin; Zachary Zeidler; Kristen Moulton; Leland Krych; Zengyan Xia; Carolyn B Smith
Journal:  Behav Brain Res       Date:  2015-05-12       Impact factor: 3.332

2.  Seizing an opportunity for the endocannabinoid system.

Authors:  Bradley E Alger
Journal:  Epilepsy Curr       Date:  2014-09       Impact factor: 7.500

Review 3.  Treatment of the psychiatric problems associated with fragile X syndrome.

Authors:  Randi J Hagerman; Jonathan Polussa
Journal:  Curr Opin Psychiatry       Date:  2015-03       Impact factor: 4.741

4.  Anandamide and 2-arachidonoylglycerol differentially modulate autistic-like traits in a genetic model of autism based on FMR1 deletion in rats.

Authors:  Sara Schiavi; Antonia Manduca; Emilia Carbone; Valeria Buzzelli; Alessandro Rava; Alessandro Feo; Fabrizio Ascone; Maria Morena; Patrizia Campolongo; Matthew N Hill; Viviana Trezza
Journal:  Neuropsychopharmacology       Date:  2022-09-16       Impact factor: 8.294

Review 5.  Endocannabinoids at the synapse and beyond: implications for neuropsychiatric disease pathophysiology and treatment.

Authors:  Andrew Scheyer; Farhana Yasmin; Saptarnab Naskar; Sachin Patel
Journal:  Neuropsychopharmacology       Date:  2022-09-13       Impact factor: 8.294

6.  Quantitative profiling of brain lipid raft proteome in a mouse model of fragile X syndrome.

Authors:  Magdalena Kalinowska; Catherine Castillo; Anna Francesconi
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

7.  Antipurinergic therapy corrects the autism-like features in the Fragile X (Fmr1 knockout) mouse model.

Authors:  Jane C Naviaux; Lin Wang; Kefeng Li; A Taylor Bright; William A Alaynick; Kenneth R Williams; Susan B Powell; Robert K Naviaux
Journal:  Mol Autism       Date:  2015-01-13       Impact factor: 7.509

Review 8.  Synaptic Plasticity, a Prominent Contributor to the Anxiety in Fragile X Syndrome.

Authors:  Tao Yang; Huan Zhao; Changbo Lu; Xiaoyu Li; Yingli Xie; Hao Fu; Hui Xu
Journal:  Neural Plast       Date:  2016-04-28       Impact factor: 3.599

9.  Endocannabinoids modulate cortical development by configuring Slit2/Robo1 signalling.

Authors:  Alán Alpár; Giuseppe Tortoriello; Daniela Calvigioni; Micah J Niphakis; Ivan Milenkovic; Joanne Bakker; Gary A Cameron; János Hanics; Claudia V Morris; János Fuzik; Gabor G Kovacs; Benjamin F Cravatt; John G Parnavelas; William D Andrews; Yasmin L Hurd; Erik Keimpema; Tibor Harkany
Journal:  Nat Commun       Date:  2014-07-17       Impact factor: 14.919

Review 10.  Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes.

Authors:  Hansen Wang; Sandipan Pati; Lucas Pozzo-Miller; Laurie C Doering
Journal:  Front Cell Neurosci       Date:  2015-02-26       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.